Absci Corp. (ABSI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.82+0.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ABSI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -19.8% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 40.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ABSI — earnings in line
Dated 2026-08-11
of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Why it matters: New partnerships may improve Absci's resources and trust. This helps in making drugs and reaching markets.
Supportive ifAnnouncement of one or more partnerships with Large Pharma companies.
Worry ifNo partnerships announced by the end of 2026, indicating stalled growth.
Why it matters: This funding will help ongoing clinical trials. Success shows financial stability.
Supportive ifThe funding closes successfully. Money is now for ABS-201's development.
Worry ifThe offering fails to close or raises less than expected.
Why it matters: The recent debt issuance could affect the company's financial health and investor sentiment. How the market reacts is key.
Watch forShare price stays steady or goes up after the debt announcement. This shows market support.
Also watch forShare price drops a lot after the announcement. This shows investor worries about debt.
Why it matters: The cash balance will indicate if Absci can fund its operations and trials effectively. A significant drop could raise concerns.
Watch forCash balance goes up or stays the same after the $100 million offering.
Also watch forCash balance drops a lot after the offering. This raises funding worries.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$347 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $778 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,400 loss on $10,000 · 54.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cash updates will show the company's financial health. A strong cash position helps keep things running.
Supportive ifCash and equivalents are more than $200 million. This shows strong liquidity.
Worry ifCash and equivalents fall below $200 million without new funding.
Why it matters: Progress on ABS-202 shows Absci can innovate and grow. It may attract investors.
Supportive ifThere is news of big progress or data from the ABS-202 program.
Worry ifNo updates or delays in the ABS-202 program development.
Why it matters: Management needs to fund operations until 2028. Updates can change how investors feel.
Supportive ifManagement shares news of a successful funding round or a new partnership.
Worry ifManagement mentions delays or issues in getting the funding they need.
Why it matters: Updates on safety and how it works will show if the drug is good. Good news can help investors feel more confident.
Watch forSafety data shows no serious side effects. It also shows good drug absorption.
Also watch forThere are reports of serious side effects. The drug absorption data is also poor.
Why it matters: If healthcare sector revenue growth speeds up, it could benefit Absci's performance. This is a key indicator.
Supportive ifHealthcare sector revenue growth speeds up again, reaching over 9%.
Worry ifHealthcare sector revenue growth slows down, falling below 9%.
Why it matters: This data will show if ABS-201 is effective for hair loss. Positive results could boost investor confidence.
Supportive ifInterim data for ABS-201 shows strong hair regrowth. This is better than current treatments.
Worry ifInterim data shows no real change in hair regrowth. This is compared to placebo.
Why it matters: Starting this trial shows progress for Absci. It may lead to new treatment options.
Supportive ifThe Phase 2 trial for ABS-201 is starting. It targets endometriosis.
Worry ifNo announcement of the Phase 2 trial initiation by the end of 2026.
Why it matters: Having enough cash is key for operations and growth. Updates can affect investor trust.
Watch forCash reserves are over $200 million. This confirms funding until 2028.
Also watch forCash reserves fell below $150 million. This raises worries about funding.